Brokers name 3 ASX shares to buy right now

Brokers have named Harvey Norman Holdings Limited (ASX:HVN) and these ASX shares as buys this week. Here's why they are bullish…

| More on:
sign containing the words buy now, asx growth shares ANZ Bank broker upgrade

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Australia's top brokers have been busy adjusting their estimates and recommendations again, leading to the release of a large number of broker notes this week.

Three broker buy ratings that have caught my eye are summarised below. Here's why brokers think these ASX shares are in the buy zone:

Harvey Norman Holdings Limited (ASX: HVN)

According to a note out of Citi, its analysts have retained their buy rating and lifted the price target on this retailer's shares to $4.50. The broker was pleasantly surprised with Harvey Norman's sales growth during April and May. And while it isn't clear whether its bottom line is growing as strongly, Citi appears confident that the company will deliver a solid full year result in August. I agree with Citi and feel Harvey Norman could be a decent option.

Newcrest Mining Limited (ASX: NCM)

Analysts at UBS have retained their buy rating and $35.00 price target on this gold miner's shares. This follows the release of drilling results from Red Chris and Havieron this week. UBS was pleased with the results from Havieron and believes they are strong enough for management to seriously consider mining the orebody. It doesn't feel this potential has been priced into its shares. I think UBS makes some good points and Newcrest could be worth considering if you're looking for exposure to gold.

Opthea Ltd (ASX: OPT)

A note out of Goldman Sachs reveals that its analysts have retained their conviction buy rating and $5.20 price target on this biotech company's shares. This follows the release of data from its study evaluating OPT-302 in the treatment of Diabetic Macular Edema. Goldman notes that the data was unconvincing and has raised more questions than answers. Nevertheless, the broker believes the near-term story remains broadly unchanged. This is because OPT-302 has already demonstrated a statistically significant benefit in a larger trial for Wet Age-Related Macular Degeneration. This has a significant market opportunity. I agree with Goldman Sachs and think Opthea could be a top long term option.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A group of young ASX investors sitting around a laptop with an older lady standing behind them explaining how investing works.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Three people gather around a large computer screen where they are looking at something that is captivating their interest with a graphic image of data and digital technology material superimposed to the right hand third of the image.
Share Market News

Here's how the ASX 200 market sectors stacked up last week

ASX tech shares led the market for a third consecutive week with a 4.63% increase.

Read more »

Mini house on a laptop.
Dividend Investing

Do ASX 200 dividend shares out-earn Aussie property?

We compare the forecast FY25 dividend yields of the top 10 ASX 200 companies to rental property yields.

Read more »

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Best Shares

Top ASX shares to buy with $500 in November 2024

$500 worth of ASX shares might not sound like a huge investment. But, to realise the benefits of compounding, you…

Read more »

A diverse group of people form a circle at a park and raise their arms together.
Share Market News

Here are the top 10 ASX 200 shares today

ASX investors ended the trading week on a high note this Friday...

Read more »

Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Catapult, De Grey Mining, Domino's, and Nufarm shares are charging higher

These shares are ending the week strongly. But why?

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »